fundvisualizer.com

BNY Mellon Global Equity Income - ADEQAX

Performance (before sales charge)

As of 08/31/2023

All information is historical and not indicative of future results. Current performance may be lower or higher than the quoted past performance, which cannot guarantee results. Share price, principal value, and return will vary, and you may have a gain or a loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. After-sales-charge returns reflect the maximum sales charge applicable to the fund. Performance may not reflect any expense limitation or subsidies currently in effect. Short-term trading fees may apply. To obtain the most recent month-end performance, visit Morningstar.com.

Asset allocation

As of 07/31/2023
Stock
45.04%
Non-U.S. Stock
52.84%
Bond
0.00%
Non-U.S. Bond
0.00%
Preferred
0.00%
Convertible
0.00%
Cash
2.13%
Other
0.00%

Due to rounding, percentages may not equal 100%.

Sectors

As of 07/31/2023

Basic materials

2.83%

Consumer cyclical

8.20%

Financial services

17.92%

Real estate

0.60%

Consumer defensive

13.49%

Health care

16.49%

Utilities

7.68%

Communication services

4.01%

Energy

5.10%

Industrials

9.72%

Technology

11.83%

Top 10 holdings

As of 07/31/2023

Sanofi SA
3.41%
Roche Holding AG
3.17%
Cisco Systems Inc
3.05%
CME Group Inc Class A
2.92%
Medtronic PLC
2.82%
PepsiCo Inc
2.60%
AbbVie Inc
2.52%
Munchener Ruckversicherungs-Gesellschaft AG
2.46%
Exelon Corp
2.41%
Bayer AG
2.31%
Fund assets

$338.61 Million

Share class

A

Morningstar category

Global Large-Stock Value

Expense ratio

1.17%

Investment objective

Equity-Income

Documents